Impact of Body Weight Loss During Preoperative Chemoradiotherapy on Prognosis of Patients With Lower Rectal Cancer
Authors:
Open Access
- 15 December 2025
- journal article
- Published by Wiley in Annals of Gastroenterological Surgery
- Vol. 10 (3) , 722-738
Abstract
Background: Preoperative chemoradiotherapy is the standard treatment for locally advanced rectal cancer (LARC), but may cause body composition changes. The prognostic impact of these changes remains unclear. The present study investigated the relationship between changes in body weight and composition during chemoradiotherapy, such as the psoas muscle mass index, visceral fat index, and subcutaneous fat index (SFI) obtained from computed tomography images, and long‐term outcomes in LARC patients. Methods: This retrospective study included 343 patients with LARC treated with preoperative chemoradiotherapy followed by curative resection between 2005 and 2023 at our hospital. Changes in body composition during chemoradiotherapy were retrospectively assessed, and the relationship between each index and long‐term outcomes was examined. Results: Forty‐one patients had body weight loss ≥ 10% during chemoradiotherapy, which correlated with reductions in 5‐year overall survival (OS) (68.2% vs. 90.5%, p < 0.001) and disease‐free survival (DFS) (53.5% vs. 70.9%, p = 0.005) rates. SFI loss ≥ 22.0% was also associated with a lower 5‐year OS rate (74.3% vs. 88.3%, p < 0.001). A multivariate analysis identified body weight loss ≥ 10% (HR 2.98, p = 0.001) and SFI loss ≥ 22.0% (HR 2.84, p = 0.007) as independent predictors of worse OS. Body weight loss ≥ 10% was also independently associated with worse DFS (HR 1.79, p = 0.014). Pre‐chemoradiotherapy body mass index ≥ 25 kg/m 2 and the cT4 factor had high odds ratios for body weight loss ≥ 10% during chemoradiotherapy. Conclusion: Body weight loss during preoperative chemoradiotherapy is an independent predictor of worse OS and DFS in LARC.Keywords
This publication has 35 references indexed in Scilit:
- Low skeletal muscle mass is a predictor of treatment related toxicity in oncologic patients. A meta-analysisClinical Nutrition, 2021
- The association between diarrhea and serum cytokines in patients with gynecologic cancer treated with surgery and pelvic chemoradiotherapyClinical and Translational Radiation Oncology, 2021
- Assessment of malnutrition by unintentional weight loss and its implications on oncologic outcomes in patient with locally advanced cervical cancer receiving primary chemoradiationGynecologic Oncology, 2021
- Prognostic significance of sarcopenia and skeletal muscle mass change during preoperative chemoradiotherapy in locally advanced rectal cancerClinical Nutrition, 2020
- Muscle wasting and survival following pre-operative chemoradiotherapy for locally advanced rectal carcinomaClinical Nutrition, 2018
- Association Between Changes in Body Composition and Neoadjuvant Treatment for Pancreatic CancerJAMA Surgery, 2018
- Proposal for new diagnostic criteria for low skeletal muscle mass based on computed tomography imaging in Asian adultsNutrition, 2016
- Cachexia and sarcopenia: mechanisms and potential targets for interventionCurrent Opinion in Pharmacology, 2015
- Gender affects acute organ toxicity during radiochemotherapy for rectal cancer: Long-term results of the German CAO/ARO/AIO-94 phase III trialRadiotherapy and Oncology, 2013
- The pivotal role of cytokines in muscle wasting during cancerThe International Journal of Biochemistry & Cell Biology, 2005